Who are in the management team of Divi's Lab.?

As of March 2022, the management team of Divi's Lab includes Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several other directors and independent members responsible for the company's strategic direction.

As of March 2022, the management team of Divi's Lab includes the following key individuals:<BR><BR>1. Murali K Divi - Chairman & Managing Director<BR>2. N V Ramana - Executive Director<BR>3. Madhusudana Rao Divi - Whole Time Director (Projects)<BR>4. Kiran S Divi - Whole Time Director & CEO<BR>5. Nilima Motaparti - Whole Time Director - Commercial<BR>6. G Suresh Kumar - Independent Director<BR>7. Ranga Rao Ravipati - Independent Director<BR>8. K V K Seshavataram - Independent Director<BR>9. Ramesh B V Nimmagadda - Chairman (Non-Executive) & Independent Director<BR>10. S Ganapaty - Independent Director<BR>11. Sunaina Singh - Independent Director<BR>12. Kosaraju Veerayya Chowdary - Independent Director<BR>13. Satish Choudhury - Company Secretary & Compliance Officer<BR><BR>This team is responsible for the strategic direction and management of the company.

What does Divi's Lab. do?

Divi's Laboratories Limited is a prominent pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals. As of March 2025, it reported net sales of ₹2,585 Cr and a net profit of ₹662 Cr, with a market cap of ₹173,306 Cr.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in the year 1990. The latest quarterly results reported are for March 2025, showcasing the company's ongoing operations and market presence.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,585 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 662 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 173,306 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 80.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.45%<BR>- Debt-Equity: -0.25<BR>- Return on Equity: 14.64%<BR>- Price to Book: 11.74<BR><BR>Contact Details:<BR>Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032<BR>Tel: 91-40-23786300/23786352/400<BR>Email: mail@divislabs.com<BR>Website: http://www.divislaboratories.com

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.

Who are the peers of the Divi's Lab.?

Divi's Lab. peers include Sun Pharma, Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab. Divi's Lab. has the highest 1-year return at 51.69% among its peers, while Zydus Lifesci. has the lowest at -10.04%.

Peers: The peers of Divi's Lab. are Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, Abbott India, and Alkem Lab.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Torrent Pharma, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab., while Average management risk is found at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., and Lupin, while Divi's Lab., Torrent Pharma, and Aurobindo Pharma show below average growth. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Mankind Pharma, Zydus Lifesci., Aurobindo Pharma, and Abbott India, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has a 1-year return of 51.69%, which is the highest among its peers, while Zydus Lifesci. has the lowest at -10.04%. Additionally, peers with negative six-month returns include Sun Pharma.Inds., Cipla, Torrent Pharma, Mankind Pharma, Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

How big is Divi's Lab.?

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, with recent net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr. The company has shareholder's funds of 14,969.00 Cr and total assets of 16,921.00 Cr.

As of 24th July, Divis Laboratories Ltd has a market capitalization of 176,072.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Divis Laboratories reported net sales of 9,360.00 Cr and a net profit of 2,191.00 Cr.<BR><BR>For the latest annual period ending March 2025, the company has shareholder's funds amounting to 14,969.00 Cr and total assets of 16,921.00 Cr.

When is the next results date for Divi's Lab.?

Divi's Lab. will announce its results on 07 November 2025.

Divi's Lab. will declare its results on 07 November 2025.

Are Divi's Lab. latest results good or bad?

Divi's Laboratories reported strong Q2 FY26 results, with a net profit of ₹689 crores (up 35.10% year-on-year) and revenue growth of 16.12% to ₹2,715 crores. The company's improved operating margin and debt-free balance sheet indicate solid performance and financial stability, making the results overall positive.

Divi's Laboratories has reported strong results for Q2 FY26, indicating a positive performance overall. The company achieved a net profit of ₹689 crores, which represents a remarkable year-on-year increase of 35.10%. Additionally, revenue grew by 16.12% compared to the same quarter last year, reaching ₹2,715 crores. This growth reflects a solid recovery and operational efficiency, especially as the operating margin improved to 32.71%, up from 30.62% in the previous year.<BR><BR>The company's profitability metrics are also encouraging, with a profit after tax margin expanding to 25.38% from 21.81% a year ago. Furthermore, Divi's Laboratories maintains a debt-free balance sheet, which enhances its financial stability and strategic flexibility.<BR><BR>Overall, the latest results can be characterized as good, showcasing strong growth and operational excellence despite competitive pressures in the pharmaceutical market.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

Should I buy, sell or hold Divi's Lab.?

Which are the latest news on Divi's Lab.?

Why is Divi's Lab. falling/rising?

As of 03-Dec, Divis Laboratories Ltd's stock price is rising to 6,451.55, indicating a potential recovery in investor sentiment after a trend reversal. Increased investor participation and strong financial performance further support the stock's upward trajectory.

As of 03-Dec, Divis Laboratories Ltd's stock price is rising, currently at 6,451.55, with a change of 34.85 (0.54%) upward. This increase follows a trend reversal after four consecutive days of decline, indicating a potential recovery in investor sentiment. The stock has outperformed its sector by 0.55% today, which suggests that it is gaining traction relative to its peers.<BR><BR>Additionally, there has been a notable increase in investor participation, with delivery volume rising by 22.97% against the 5-day average, reaching 93.92k on 02 Dec. This uptick in trading activity may reflect growing confidence among investors. The stock's current price is also higher than its 50-day, 100-day, and 200-day moving averages, although it remains below its 5-day and 20-day moving averages, indicating mixed short-term momentum.<BR><BR>Furthermore, the company has demonstrated strong financial performance, with high management efficiency reflected in a return on equity (ROE) of 17.24% and a low debt-to-equity ratio of 0 times. Positive results over the last five consecutive quarters, including record net sales and dividends, contribute to a favorable outlook. The stock has also shown market-beating performance over the long term, generating a 3.92% return in the last year and significantly outperforming the BSE500 over the past three years.<BR><BR>Overall, the combination of improved trading activity, strong financial metrics, and a recent trend reversal supports the stock's rising price.